documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
11 rows where docket_id = "FDA-2026-N-2590" sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_month, open_for_comment, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2026-N-2590-0003 | FDA | Microbiology Devices; Reclassification of Mycobacterium tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests FDA-2026-N-2590 | List of References_FDA-2026-N-2590 | Supporting & Related Material | Background Material | 2026-04-20T04:00:00Z | 2026 | 4 | 2026-04-20T20:30:47Z | 0 | 0 | 09000064b9281c66 | |||
| FDA-2026-N-2590-0007 | FDA | Microbiology Devices; Reclassification of Mycobacterium tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests FDA-2026-N-2590 | Reference 4 - P180047 Summary of Safety and Effectiveness Data | Supporting & Related Material | Background Material | 2026-04-20T04:00:00Z | 2026 | 4 | 2026-04-20T20:31:22Z | 0 | 0 | 09000064b9288104 | |||
| FDA-2026-N-2590-0008 | FDA | Microbiology Devices; Reclassification of Mycobacterium tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests FDA-2026-N-2590 | Reference 5 - P070006 Summary of Safety and Effectiveness Data | Supporting & Related Material | Background Material | 2026-04-20T04:00:00Z | 2026 | 4 | 2026-04-20T20:31:25Z | 0 | 0 | 09000064b9288105 | |||
| FDA-2026-N-2590-0010 | FDA | Microbiology Devices; Reclassification of Mycobacterium tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests FDA-2026-N-2590 | Reference 7 - 2023_ Microbiology Devices Panel of the Medical Devices Advisory Committee Meeting Announcement | Supporting & Related Material | Background Material | 2026-04-20T04:00:00Z | 2026 | 4 | 2026-04-20T20:31:31Z | 0 | 0 | 09000064b9288107 | |||
| FDA-2026-N-2590-0011 | FDA | Microbiology Devices; Reclassification of Mycobacterium tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests FDA-2026-N-2590 | Reference 8 - Diagnosis of Tuberculosis in Adults and Children | Supporting & Related Material | Background Material | 2026-04-20T04:00:00Z | 2026 | 4 | 2026-04-20T20:31:35Z | 0 | 0 | 09000064b9288108 | |||
| FDA-2026-N-2590-0005 | FDA | Microbiology Devices; Reclassification of Mycobacterium tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests FDA-2026-N-2590 | Reference 2 - 2001 Microbiology Devices Panel Meeting Summary | Supporting & Related Material | Background Material | 2026-04-20T04:00:00Z | 2026 | 4 | 2026-04-20T20:31:03Z | 0 | 0 | 09000064b9288102 | |||
| FDA-2026-N-2590-0012 | FDA | Microbiology Devices; Reclassification of Mycobacterium tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests FDA-2026-N-2590 | Reference 9 - Treatment of Drug-Susceptible Tuberculosis | Supporting & Related Material | Background Material | 2026-04-20T04:00:00Z | 2026 | 4 | 2026-04-20T20:31:37Z | 0 | 0 | 09000064b9288109 | |||
| FDA-2026-N-2590-0006 | FDA | Microbiology Devices; Reclassification of Mycobacterium tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests FDA-2026-N-2590 | Reference 3 - P010033 Summary of Safety and Effectiveness Data | Supporting & Related Material | Background Material | 2026-04-20T04:00:00Z | 2026 | 4 | 2026-04-20T20:31:19Z | 0 | 0 | 09000064b9288103 | |||
| FDA-2026-N-2590-0009 | FDA | Microbiology Devices; Reclassification of Mycobacterium tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests FDA-2026-N-2590 | Reference 6 - 2011 Meeting Materials of the Microbiology Devices Panel | Supporting & Related Material | Background Material | 2026-04-20T04:00:00Z | 2026 | 4 | 2026-04-20T20:31:28Z | 0 | 0 | 09000064b9288106 | |||
| FDA-2026-N-2590-0004 | FDA | Microbiology Devices; Reclassification of Mycobacterium tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests FDA-2026-N-2590 | Reference 1 - P010033 Approval Order | Supporting & Related Material | Background Material | 2026-04-20T04:00:00Z | 2026 | 4 | 2026-04-20T20:31:00Z | 0 | 0 | 09000064b9288101 | |||
| FDA-2026-N-2590-0001 | FDA | Microbiology Devices; Reclassification of Mycobacterium tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests FDA-2026-N-2590 | Microbiology Devices; Reclassification of Mycobacterium Tuberculosis Cell-Mediated Immunity Tests and Immune Response Enzyme-Linked Immunospot Tests | Proposed Rule | Request for Comment | 2026-03-30T04:00:00Z | 2026 | 3 | 2026-03-30T04:00:00Z | 2026-05-30T03:59:59Z | 2026-05-13T09:00:24Z | 2026-06064 | 1 | 0 | 09000064b92437b6 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;